{"nctId":"NCT03689374","briefTitle":"A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes","startDateStruct":{"date":"2018-10-01","type":"ACTUAL"},"conditions":["Diabetes Mellitus, Type 2"],"count":2274,"armGroups":[{"label":"Semaglutide","type":"EXPERIMENTAL","interventionNames":["Drug: Semaglutide","Drug: Insulin glargine U100"]},{"label":"Insulin aspart","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Insulin aspart","Drug: Insulin glargine U100"]}],"interventions":[{"name":"Semaglutide","otherNames":[]},{"name":"Insulin aspart","otherNames":[]},{"name":"Insulin glargine U100","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, age greater than or equal to 18 years at the time of signing informed consent\n* Diagnosed with type 2 diabetes greater than or equal to 180 days prior to the day of screening\n* Treated with basal insulin once daily or twice daily for greater than or equal to 90 days prior to the day of screening\n* Stable daily dose for 90 days prior to the day of screening of the following anti-diabetic drugs or combination regimens: Any metformin formulations (greater than or equal to 1500 mg to less than or equal to 3000 mg or maximum tolerated or effective dose documented in subject's medical record), alone or in combination (including fixed-dose drug combination) with up to one additional of the following oral antidiabetic drugs: sulfonylureas, meglitinides, dipeptidyl peptidase-4 inhibitors or alpha-glucosidase inhibitors\n* Glycated haemoglobin (HbA1c) of greater than 7.5% to less than or less than or equal to 10.0% (greater than 58 mmol/mol to less than or equal to 86 mmol/mol)\n\nExclusion Criteria:\n\n* History or presence of pancreatitis (acute or chronic)\n* Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening\n* Subjects presently classified as being in New York Heart Association Class IV\n* Planned coronary, carotid or peripheral artery revascularisation known on the day of screening\n* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening. However, short term bolus insulin treatment for a maximum of 14 days prior to the day of screening is allowed\n* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a pharmacologically pupil-dilated fundus examination performed by an ophthalmologist or an equally qualified health care provider (for example, optometrist) within the past 90 days prior to run-in","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Glycated Haemoglobin (HbA1c)","description":"Change from baseline in HbA1c at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"1.0"},{"groupId":"OG001","value":"-1.2","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Time to First Event Adjudication Committee (EAC)-Confirmed Severe Hypoglycaemic Episode American Diabetes Association (ADA) From Randomization up to Week 52","description":"First event per 100 years of exposure time for first EAC confirmed severe hypoglycaemic episodes from randomization (week 0) to week 52 are presented. As per 2013 ADA criteria severe hypoglycaemic episodes were episodes with plasma glucose (PG) less than or equal to (\\<=) 3.9 millimoles per liter (mmol/L) (70 milligrams per deciliter (mg/dL)). EAC confirmed-severe hypoglycaemia was an episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Event Adjudication Committee-confirmed Severe Hypoglycaemic Episode (ADA) Requiring Hospitalization, Documented Medical Help, or is Life-threatening Randomization up to Week 52","description":"First event per 100 years of exposure time for first EAC confirmed severe hypoglycaemic episodes requiring hospitalization, documented medical help, or is life threatening from randomization (week 0) to week 52 are presented. As per 2013 ADA criteria severe hypoglycaemic episodes were episodes with PG \\<=3.9 mmol/L (70 mg/dL). EAC confirmed-severe hypoglycaemia was an episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Event Adjudication Committee-confirmed Severe Hypoglycaemic Episodes (ADA) From Randomization to Week 52","description":"Number of EAC-confirmed severe hypoglycaemic episodes from randomization (week 0) up to week 52 are presented. As per 2013 ADA criteria severe hypoglycaemic episodes were episodes with PG \\<=3.9 mmol/L (70 mg/dL). EAC confirmed-severe hypoglycaemia was an episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Event Adjudication Committee-confirmed Severe (ADA) or Blood Glucose (BG) Confirmed, Symptomatic Hypoglycaemic Episodes (Plasma Glucose Less Than (<) 3.1 mmol/L (56 mg/dL)) From Randomization to Week 52","description":"Number of EAC-confirmed severe or BG confirmed, symptomatic hypoglycaemic episodes (PG \\<3.1 mmol/L (56 mg/dL)) from randomization (week 0) to week 52 are presented. As per 2013 ADA criteria severe hypoglycaemic episodes were episodes with PG \\<=3.9 mmol/L (70 mg/dL). Severe or BG confirmed symptomatic hypoglycaemia was an episode, that was BG confirmed by PG value \\<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"254","spread":null},{"groupId":"OG001","value":"1744","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Event Adjudication Committee-confirmed Severe (ADA) or Blood Glucose Confirmed, Symptomatic Hypoglycaemic Episodes (Plasma Glucose <= 3.9 mmol/L (70 mg/dL)) From Randomization to Week 52","description":"Number of EAC-confirmed severe or BG confirmed, symptomatic hypoglycaemic episodes (PG \\<=3.9 mmol/L (70 mg/dL)) from randomization (week 0) to week 52 are presented. As per 2013 ADA criteria severe hypoglycaemic episodes were episodes with PG \\<=3.9 mmol/L (70 mg/dL). Severe or BG confirmed symptomatic hypoglycaemia was an episode during which symptoms of hypoglycaemia were not accompanied by a PG determination but that was presumably caused by a PG concentration \\<= 3.9 mmol/L (70 mg/dL). Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1420","spread":null},{"groupId":"OG001","value":"5616","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Event Adjudication Committee-confirmed Severe Hypoglycaemic Episodes (ADA) Requiring Hospitalization, Documented Medical Help, or is Life-threatening From Randomization to Week 52","description":"Number of EAC-confirmed severe hypoglycaemic episodes requiring hospitalization, documented medical help, or is life-threatening from randomization (week 0) to week 52 are presented. As per 2013 ADA criteria severe hypoglycaemic episodes were episodes with PG \\<=3.9 mmol/L (70 mg/dL). Severe hypoglycaemia was an episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Event Adjudication Committee-confirmed Severe (ADA) or Clinically Significant Hypoglycaemic Episodes (Plasma Glucose < 3.0 mmol/L (54 mg/dL)) From Randomization to Week 52","description":"Number of EAC-confirmed severe or clinically significant hypoglycaemic episodes (plasma glucose \\< 3.0 mmol/L (54 mg/dL)) from randomization (week 0) to week 52 are presented. As per 2013 ADA criteria severe hypoglycaemic episodes were episodes with PG \\<=3.9 mmol/L (70 mg/dL). Severe hypoglycaemia was an episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. Hypoglycaemic episode with plasma glucose \\< 3.0 mmol/L (54 mg/dL)) was considered as clinically significant. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"339","spread":null},{"groupId":"OG001","value":"2270","spread":null}]}]}]},{"type":"SECONDARY","title":"Daily Basal Insulin Dose at Week 52","description":"Daily basal insulin dose at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.8","spread":"19.4"},{"groupId":"OG001","value":"40.7","spread":"22.0"}]}]}]},{"type":"SECONDARY","title":"Total Daily Insulin Dose at Week 52","description":"Total daily insulin dose at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.8","spread":"19.4"},{"groupId":"OG001","value":"77.7","spread":"40.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Body Weight (Kilogram (kg))","description":"Change from baseline in body weight at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"4.6"},{"groupId":"OG001","value":"2.9","spread":"4.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Fasting Plasma Glucose (FPG)","description":"Change from baseline in FPG at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"2.9"},{"groupId":"OG001","value":"-0.8","spread":"3.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in 7-point Self-measured Plasma Glucose Profile (SMPG ): Mean 7-point Profile (7-PP)","description":"Change from baseline in 7-point self-measured plasma glucose profile: mean 7-PP at week 52 is presented. All participants were instructed to perform 7-point SMPG profiles before breakfast, 90 minutes after the start of breakfast, before lunch, 90 minutes after the start of lunch, before main evening meal (dinner), 90 minutes after the start of main evening meal (dinner) and at bedtime. The measurements were to be performed before any injection of bolus insulin and just before the start of the meal (breakfast, lunch or main evening meal), and values measured before breakfast were performed in a fasting condition. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"2.0"},{"groupId":"OG001","value":"-2.1","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in 7-point Self-measured Plasma Glucose Profile: Mean Post-prandial Increment (Over All Meals)","description":"Change from baseline in 7-point SMPG profile: mean post-prandial increment (over all meals) at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"1.8"},{"groupId":"OG001","value":"-0.9","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Body Mass Index (BMI)","description":"Change from baseline in BMI at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"1.7"},{"groupId":"OG001","value":"1.0","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Waist Circumference","description":"Change from baseline in waist circumference at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"5.6"},{"groupId":"OG001","value":"2.1","spread":"4.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Body Weight (Percentage): Ratio to Baseline","description":"Change from baseline in body weight (measured in percentage) at week 52 is presented as ratio to baseline. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"0.1"},{"groupId":"OG001","value":"1.0","spread":"0.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Fasting Blood Lipids: Total Cholesterol (Ratio to Baseline)","description":"Change from baseline in total cholesterol (measured in mmol/L) at week 52 is presented as ratio to baseline. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"19.6"},{"groupId":"OG001","value":"1.0","spread":"20.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Fasting Blood Lipids: Low-density Lipoprotein (LDL) Cholesterol (Ratio to Baseline)","description":"Change from baseline in LDL cholesterol (measured in mmol/L) at week 52 is presented as ratio to baseline. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"36.2"},{"groupId":"OG001","value":"1.0","spread":"35.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Fasting Blood Lipids: High-density Lipoprotein (HDL) Cholesterol (Ratio to Baseline)","description":"Change from baseline in HDL cholesterol (measured in mmol/L) at week 52 is presented as ratio to baseline. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"16.7"},{"groupId":"OG001","value":"1.0","spread":"16.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Fasting Blood Lipids: Triglycerides (Ratio to Baseline)","description":"Change from baseline in triglycerides (measured in mmol/L) at week 52 is presented as ratio to baseline. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"40.4"},{"groupId":"OG001","value":"1.0","spread":"42.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Systolic and Diastolic Blood Pressure","description":"Change from baseline in systolic and diastolic blood pressure at week 52 are presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"8.7"},{"groupId":"OG001","value":"-0.4","spread":"9.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"13.8"},{"groupId":"OG001","value":"1.0","spread":"14.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Pulse Rate","description":"Change from baseline in pulse rate at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"8.7"},{"groupId":"OG001","value":"1.1","spread":"8.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in 36-item Short Form Health Survey Version 2 (SF-36v2): Total Summary Scores (Physical Component and Mental Component) and Scores From the 8 Domains","description":"SF-36v2 is 36-item patient-reported survey of patient health to measure participant's overall health-related quality of life (HRQoL). It has 36 items: 8 domains of physical, mental health status (physical functioning, role physical health (range:21.23-57.16), bodily pain (range: 21.68-62.00), general health (range: 18.95-66.50), vitality (range: 22.89-70.42), social functioning (range: 17.23-57.34), role emotional problem (range: 14.39-56.17) and mental health (range: 11.63-63.95)) and 2 total summary scores: physical components summary (range: 7.32-70.14) and mental components summary (range: 5.79-69.91) calculated from domain scores. All 10 scores range from 5.79-70.42 . Higher scores indicated a better health state. Change from baseline in SF-36v2, 2 summary and 8 domains scores at week 52 is presented. Data is reported for 'on-treatment' observation period: from date of first dose of trial product (week 0) to last date on trial product with a visit window of +7 days (week 52).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"6.4"},{"groupId":"OG001","value":"0.4","spread":"6.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"8.6"},{"groupId":"OG001","value":"-0.3","spread":"8.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"7.7"},{"groupId":"OG001","value":"0.2","spread":"7.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"7.8"},{"groupId":"OG001","value":"-0.2","spread":"8.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"9.0"},{"groupId":"OG001","value":"0.8","spread":"9.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"8.0"},{"groupId":"OG001","value":"0.3","spread":"8.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"8.6"},{"groupId":"OG001","value":"0.1","spread":"7.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"9.5"},{"groupId":"OG001","value":"-0.6","spread":"9.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"9.4"},{"groupId":"OG001","value":"-0.2","spread":"9.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"8.7"},{"groupId":"OG001","value":"0.1","spread":"8.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Diabetes Quality of Life Clinical Trial Questionnaire (DQLCTQ-R): Scores From the 8 Domains","description":"The DQLCTQ-R questionnaire was used to assess participants' HRQoL. The DQLCTQ-R questionnaire contains 57 items and measures and provide scores for the 8 domains (physical function, energy or fatigue, health distress, mental health, satisfaction, treatment satisfaction, treatment flexibility and frequency of symptoms). The 8 domain scores related to DQLCTQ-R are measured on a scale from 0-100. For all scores, higher values indicated better health status. Change from baseline in DQLCTQ-R 8 domain scores at week 52 is presented. Data is reported for 'on-treatment' observation period: from the date of first dose of trial product (week 0) to the last date on trial product with a visit window of +7 days (week 52).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"24.6"},{"groupId":"OG001","value":"-0.4","spread":"26.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"13.0"},{"groupId":"OG001","value":"0.4","spread":"12.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"12.4"},{"groupId":"OG001","value":"0.3","spread":"13.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"18.5"},{"groupId":"OG001","value":"0.5","spread":"20.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"18.6"},{"groupId":"OG001","value":"-0.2","spread":"16.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":"23.9"},{"groupId":"OG001","value":"0.8","spread":"24.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"20.1"},{"groupId":"OG001","value":"-1.2","spread":"19.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"15.5"},{"groupId":"OG001","value":"1.8","spread":"14.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":65,"n":874},"commonTop":["Nausea","Nasopharyngitis","Diarrhoea","Vomiting"]}}}